Fibric acid derivatives increase risk of myopathy/rhabdomyolysis. Caution should be used when prescribing together.
Source: NLP:atorvastatin calcium
Fibrates Interactions
21 interactions on record
Fibrates + EzetimibeMajor
Co-administration of ezetimibe with fibrates other than fenofibrate is not recommended until adequately studied due to potential cholelithiasis risk.
Source: NLP:ezetimibe
Fibrates may cause myopathy when used alone; concomitant use with fluvastatin increases risk of myopathy and rhabdomyolysis. Consider use only if benefit outweighs risk and monitor for symptoms.
Source: NLP:fluvastatin sodium
Fibrates increase the risk of myopathy and rhabdomyolysis when used concomitantly with pitavastatin. Benefit-risk assessment is recommended.
Source: NLP:pitavastatin calcium
Risk of myopathy and rhabdomyolysis is increased with concomitant use. Monitor for signs and symptoms of myopathy during initiation and dose titration.
Source: NLP:pravastatin sodium
Concomitant use with fibrates increases risk of adverse skeletal muscle effects including myopathy. Caution should be used when prescribing together.
Source: NLP:rosuvastatin calcium
Fibrates + ColchicineModerate
Other lipid-lowering drugs that may interact with colchicine. Monitor patients during coadministration.
Source: NLP:colchicine
Fibrates + GlimepirideModerate
May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
Source: NLP:glimepiride
Fibrates + GlipizideModerate
May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.
Source: NLP:glipizide
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart
Fibrates + Insulin Aspart-SzjjModerate
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
Fibrates + Insulin DegludecModerate
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec
Fibrates + Insulin GlargineModerate
May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin glargine
Fibrates + Insulin GlulisineModerate
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
Fibrates + Insulin HumanModerate
May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin human
Fibrates + Insulin LisproModerate
May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
Source: NLP:insulin lispro
Fibrates + Insulin Lispro-AabcModerate
May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
When used as an anticoagulant, citrate contributes to overall buffer load and can reduce plasma calcium levels. Appropriate PRISMASOL/PHOXILLUM formulation selection is recommended.
Source: NLP:magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride
Fibrates + PitavastatinModerate
Fibrates increase the risk of myopathy and rhabdomyolysis when used concomitantly with pitavastatin. Concomitant use requires careful benefit/risk assessment.
Source: NLP:pitavastatin
Fibrates + RosuvastatinModerate
Use with fibrates increases risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuvastatin.
Source: NLP:rosuvastatin
Fibrates + SimvastatinModerate
Caution should be used when prescribing other fibrate products with simvastatin; increases risk of adverse skeletal muscle effects.
Source: NLP:simvastatin